Exploiting mechanism-informed phenotypic screening for development of next-generation antimitotic phytochemicals

in the CNS and therapeutic resistance which are repetitively seen at the time of microtubule-targeting, the use of these drugs is limited [1-4]. The new generation of mitotic drugs aims for the mitotic regulatory machinery which involves the motor proteins, mitotic kinesins, or the Aurora and polo-like kinases and complexes which are expressed only at the time of cell division [2]. Research efforts are intended towards developing superior antimitotic drugs that would not be only more specific in their action but would also lessen the burden of side effects on patients. Also, because cancer cells demonstrate vast phenotypic miscellany they are characteristically responsive to phenotypic screening which would assist in translating the molecular mechanism as a therapeutic approach in treating cancer with familiar cellular phenotypes following the theory of mechanism-informed phenotypic screening.